Recent Patents Filings
Four Patents relating to Mushroom species grown in fermentor for cholesterol
and for antidiabetes have been allowed to grant in the USA.
Process for producing, methods and compositions of cholesterol
lowering agents from higher Basidiomycetes mushrooms.
Abstract: The present invention describes new and distinct strains
Basidiomycetes mushrooms, and a process for growing them in submerged
culture. Specifically, the new strains of species of the genus Pleurotus
offer superior yields of mushroom biomass and concentrations of biologically
active compounds, for example, cholesterol-lowering compounds, lectins,
proteins, essential amino acids, vitamins or polysaccharides. The process
include use of defined media and a simple one-step procedure of separating
the lovastins-containing nutraceuticals from culture broth.
For higher Basidiomycetes Mushrooms grown (as biomass) in submerged
culture.
Abstract: The present invention describes new and distinct
horticultural varieties of higher Basidiomycetes mushrooms grown in submerged
culture. Specifically, the new varieties of species of the genus Pleurotus
offer superior yields of mushrooms cell biomass and greater concentrations
of the protein rich in essential amino acids, fatty, acids, vitamins and
minerals.
Process for producing, methods and compositions of glucuronoxylomannan
as nutraceuticals agent form higher Basidiomycetes Mushroom.
Abstract: The present invention describes new and distinct
stains of higher Basidiomycetes grown in submerged cultures. Specifically,
the new strain of species of the genus Tremella offer superior yields
of one-cell biomass and exocellular heteropolysaccharide glucoronoxylomannan,
niacin and essential amino acids.
For higher Basidiomycetes Mushrooms grown (as one cell biomass)
in submerged culture.
Abstract: The present invention describes new and distinct
horticultural varieties of higher Basidiomycetes mushrooms grown in submerged
culture. Specially, the new varieties of species of the genus Tremella
offer superior yields of mushroom one-cell biomass rich in essential amino
acids and vitamins and polysaccharides glucuronoxylomannan.
Others
Other patents developed by the Group have been granted for the US, European
countries and Australia include patents for: -
Recent Acquisitions of Intellectual Property for Fungal Therapeutics
The Company has acquired the intellectual property relating to the isolation
and characterization of Fungal Growth Hormones called Fungi Flex 1 and
Fungi Flex 2 from Dr David Moore and Dr Lily Novak Frazer, two fungal
developmental biologists from the University of Manchester, U.K.
Fungal diseases affect plants, animals and man. Knowledge of fungal growth
hormones may well open up a very large market for specific remedies for
fungal diseases, a new class of fungal therapeutics.
The acquisition strengthens our knowledge-based Biopharmaceutical business,
and will enable us to further research into and develop new fungicides
for the world market.
Others
We also own certain proprietary information and know-how in techniques
and methods relating to the patented inventions and the production of
our nutraceutical and biopharmaceutical products.
Trade Marks
We own a number of trade marks applications and registrations worldwide
- Trade marks comprising and including the words “EVERBLOOM”,
“LINZIR” (in the English and Chinese languages) and “Mycomed”,
“MycoGlucan” and “MycoVite” cover a variety of
health and medical products and food.
Our trade marks are registered or pending registration in a number of
countries worldwide. We intend to secure registration of those marks which
are still pending acceptance and to preserve the existence of those registrations
already obtained through timely renewal.